Pfizer/J&J Alzheimer's Drug Should Get Longer Patent Life, Appeals Court Says
An appeals court ruled that the Patent and Trademark Office had miscalculated the patent term extension owed to Pfizer and Johnson & Johnson for delays in prosecuting the patent on the investigational Alzheimer's drug bapineuzumab
You may also be interested in...
Six months after announcing it was looking at strategic alternatives, Elan's beleaguered management has found a way to address its challenges: It announced July 2 that it is selling its Alzheimer's immunotherapy program (AIP), which includes the high-profile Alzheimer's disease drug bapineuzumab and all related assets, to Johnson & Johnson for what essentially amounts to $500 million in the near-term and a commitment from J&J to buy an 18.4 percent stake in Elan for $1 billion
Wyeth's Alzheimer's drug bapineuzumab won an additional eight months of patent coverage under a federal court ruling that found the U.S. Patent and Trademark Office had misinterpreted a law governing agency delays in processing patent applications
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011